MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561390 | Name: Clinofibrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clinofibrate is a lipid-lowering agent classified as a fibrate, primarily used to treat hyperlipidemia. It acts as an agonist of peroxisome proliferator-activated receptor alpha (PPAR-α), which upregulates the expression of genes involved in fatty acid oxidation and enhances lipoprotein lipase activity, leading to decreased plasma triglycerides and increased HDL cholesterol. Clinofibrate has demonstrated efficacy in reducing serum triglyceride levels and improving lipid profiles in patients with dyslipidemia.

Chemical Structure

Clinofibrate
Clinofibrate
CAS#30299-08-2

Theoretical Analysis

MedKoo Cat#: 561390

Name: Clinofibrate

CAS#: 30299-08-2

Chemical Formula: C28H36O6

Exact Mass: 468.2512

Molecular Weight: 468.59

Elemental Analysis: C, 71.77; H, 7.74; O, 20.49

Price and Availability

Size Price Availability Quantity
50mg USD 250.00 2 Weeks
200mg USD 650.00 2 Weeks
1g USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Clinofibrate; Lipoclin; S-8527; S8527; S 8527;
IUPAC/Chemical Name
2-[4-[1-[4-(2-Carboxybutan-2-yloxy)phenyl]cyclohexyl]phenoxy]-2-methylbutanoic acid
InChi Key
BMOVQUBVGICXQN-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-14-10-20(11-15-22)28(18-8-7-9-19-28)21-12-16-23(17-13-21)34-27(4,6-2)25(31)32/h10-17H,5-9,18-19H2,1-4H3,(H,29,30)(H,31,32)
SMILES Code
CCC(C)(OC1=CC=C(C2(C3=CC=C(OC(CC)(C(O)=O)C)C=C3)CCCCC2)C=C1)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 468.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Li JK, Lu C, Yang J, Li F, Ge J, Wei S, Xueqing L, Ding L, Ai-Dong W. Development of a LC-MS/MS method for the estimation of clinofibrate in human urine. Pharmazie. 2015 Apr;70(4):219-24. PubMed PMID: 26012250. 2: Li JK, Ding LK, Li XQ, Chen MC, Wang L, Yang J, Song Y, Song W, Jia YY, Wen AD. Effect of food on the single-dose pharmacokinetics and tolerability of clinofibrate tablets in Chinese healthy volunteers. Int J Clin Pharmacol Ther. 2013 Aug;51(8):672-7. PubMed PMID: 23849436. 3: Jian-Kang L, Ying S, Lei W, Minchun C, Wei S, Xueqing L, Xiao-Li S, Guangqing L, Yan-Yan J, Ai-Dong W. High-performance liquid chromatographic method for determination of clinofibrate and its application to a pharmacokinetic study in healthy volunteers. J Pharm Biomed Anal. 2013 Mar 25;76:152-6. doi: 10.1016/j.jpba.2012.12.008. Epub 2012 Dec 20. PubMed PMID: 23319135. 4: Fukami T, Takahashi S, Nakagawa N, Maruichi T, Nakajima M, Yokoi T. In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities. Drug Metab Dispos. 2010 Dec;38(12):2173-8. doi: 10.1124/dmd.110.034454. Epub 2010 Sep 1. PubMed PMID: 20810539. 5: Shuai J, Liu Y, Liu M, Liu D. 4,4'-(Cyclo-hexane-1,1-di-yl)diphenol methanol solvate. Acta Crystallogr Sect E Struct Rep Online. 2009 Jan 10;65(Pt 2):o269. doi: 10.1107/S1600536809000427. PubMed PMID: 21581883; PubMed Central PMCID: PMC2968192. 6: Tomiyama N, Yasuda N, Iwano C, Matzno S, Matsuyama K. Flow cytometric evaluation of synergistic pro-apoptotic effects of statins and clofibrates in IM-9 human lymphoblasts. Clin Exp Pharmacol Physiol. 2007 Sep;34(9):876-80. PubMed PMID: 17645633. 7: Shiina Y, Homma Y, Oguma T, Fusegawa Y, Ozawa H, Handa S, Tanabe T. A case of familial hypercholesterolemia; secession from LDL-apheresis by the drug treatment with potent statin and resin. Tokai J Exp Clin Med. 2005 Sep;30(3):149-55. PubMed PMID: 16285605. 8: Sato I, Hyakuta M, Hayashi F, Mukai M, Kondo S, Maeda E, Kumagai S. [Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia]. Rinsho Byori. 2002 Oct;50(10):987-91. Japanese. PubMed PMID: 12451680. 9: Hayashi K. Influence of fibrates on ethanol metabolism in rats. Nihon Arukoru Yakubutsu Igakkai Zasshi. 2000 Oct;35(5):306-20. PubMed PMID: 11144151. 10: Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H. Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. Kidney Int Suppl. 1999 Jul;71:S134-6. PubMed PMID: 10412757. 11: Matsuura K, Hara A, Kato M, Deyashiki Y, Miyabe Y, Ishikura S, Sugiyama T, Katagiri Y. Activation of human liver 3alpha-hydroxysteroid dehydrogenase by clofibrate derivatives. J Pharmacol Exp Ther. 1998 Jun;285(3):1096-103. PubMed PMID: 9618412. 12: Sakuma N, Iwata S, Ikeuchi R, Ichikawa T, Hibino T, Kamiya Y, Ohte N, Kawaguchi M, Kunimatsu M, Kawahara H, et al. Coexisting type III hyperlipoproteinemia and familial hypercholesterolemia: a case report. Metabolism. 1995 Apr;44(4):460-5. PubMed PMID: 7723668. 13: Okazaki M, Zhang H, Ichino K, Amamiya M, Nakayama S, Oguchi K. Effects of clinofibrate on plasma fibrinogen level in high fructose diet-induced hyperlipidemic rats. In Vivo. 1994 Nov-Dec;8(6):1057-61. PubMed PMID: 7772737. 14: Imasaka S, Nakayama S, Oguchi K. [Changes of lipids and lipoproteins in cholesterol free-high fructose diet-fed rats and the effects of clinofibrate]. Nihon Yakurigaku Zasshi. 1994 Feb;103(2):67-78. Japanese. PubMed PMID: 8112691. 15: Nishizawa Y, Shoji T, Nishitani H, Yamakawa M, Konishi T, Kawasaki K, Morii H. Hypertriglyceridemia and lowered apolipoprotein C-II/C-III ratio in uremia: effect of a fibric acid, clinofibrate. Kidney Int. 1993 Dec;44(6):1352-9. PubMed PMID: 8301936. 16: Mizuguchi K, Yano T, Kojima M, Tanaka Y, Ishibashi M, Masada A, Sato M, Mizota M, Fukutake K, Saito Y. Hypolipidemic effect of ethyl all-cis-5,8,11,14,17-eicosapentaenoate (EPA-E) in rats. Jpn J Pharmacol. 1992 Jul;59(3):307-12. PubMed PMID: 1434127. 17: Maruno H, Shimizu T, Kawai K, Hirohata K. The response of osteocytes to a lipid clearing agent in steroid-treated rabbits. J Bone Joint Surg Br. 1991 Nov;73(6):911-5. PubMed PMID: 1955435. 18: Horio T, Kohno M, Murakawa K, Yasunari K, Yokokawa K, Ueda M, Takeda T. Increased plasma immunoreactive endothelin-1 concentration in hypercholesterolemic rats. Atherosclerosis. 1991 Aug;89(2-3):239-46. PubMed PMID: 1793451. 19: McTavish D, Sorkin EM. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89. Review. Erratum in: Drugs 1991 Dec;42(6):944. PubMed PMID: 1718686. 20: Suzaki K, Kobori S, Ueno S, Uehara M, Kayashima T, Takeda H, Fukuda S, Takahashi K, Nakamura N, Uzawa H, et al. Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus. Atherosclerosis. 1990 Jan;80(3):181-9. PubMed PMID: 2310424.

View History

Pradigastat free acid

Pradigastat free acid

Hydrocortamate HCl

Hydrocortamate HCl

Zolamide sodium

Zolamide sodium

N-Me-L-Ala-maytansinol

N-Me-L-Ala-maytansinol

Ketocainol HCl

Ketocainol HCl

JQN00639

JQN00639